FULL SUPPLEMENT: The Role of IL 31 Inhibition in Atopic Dermatitis

Atopic dermatitis and prurigo nodularis represent the two most burdensome pruritic inflammatory skin diseases encountered in clinical dermatology. While distinct in morphology, chronicity, and epidemiology, both conditions are united by a common pathophysiologic axis: type 2 immune dysregulation, peripheral neuronal sensitization, collagen deposition resulting in lichenification or nodule formation, and the relentless itch-scratch cycle that profoundly impairs quality of life. At the molecular center of this axis sits interleukin-31, a cytokine that has earned the designation "the itchy cytokine" for its potent, direct pruritogenic activity.